Psoriasis Clinical Trials in Las Vegas
View 12 new treatments for Psoriasis in Las Vegas, NV, and nearby areas, such as Henderson. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Las Vegas + 2 more
The purpose of this study is to evaluate the effect of deucravacitinib on quality of life (QoL) in participants with plaque psoriasis in a community setting.
Waitlist
Phase 4
Est. 3 - 6 Weeks
Bristol-Myers Squibb
Study Director
Brodalumab for Pediatric Psoriasis
Bausch Clinic, Henderson + 1 more
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Recruiting
No Placebo Trial
Phase 4
Est. 4 - 6 Weeks
Anya Loncaric
Study Director
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Las Vegas + 1 more
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
IDP-118 Lotion for Psoriasis
Bausch Clinic, Henderson + 1 more
This trial tests a special lotion called IDP-118 for children with moderate to severe plaque psoriasis. It aims to ensure the lotion is safe, see how much gets into the body, and check if it affects stress-related hormones. The goal is to find a safe and effective treatment for these children. IDP-118 is a combination of halobetasol propionate and tazarotene, which has shown effectiveness in treating moderate-to-severe plaque psoriasis in adults.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Anya Loncaric
Study Director
Deucravacitinib for Psoriasis
Bristol-Myers Squibb Clinic, Las Vegas + 1 more
The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Bristol-Myers Squibb
Study Director
Ixekizumab + Tirzepatide for Psoriasis
Eli Lilly Clinic, Las Vegas + 2 more
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director
TAK-279 for Psoriasis
Takeda Clinic, Henderson + 2 more
The main aim of this study is to check the side effects of TAK-279 and how well it is tolerated in participants with moderate-to-severe plaque psoriasis. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 217 weeks, including up to 35 days for the screening period, 52 weeks (Part A) up to 156 additional weeks (Part B) study treatment and 4 weeks follow up period. During the study, participants will visit their study clinic multiple times.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Study Director
Study Director
Risankizumab for Pediatric Psoriasis
AbbVie Clinic, Reno + 1 more
Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study evaluates adverse events and change in disease activity with risankizumab in pediatric participants with moderate to severe plaque psoriasis who completed the study M19-977. Risankizumab is an approved drug for treatment of moderate to severe plaque psoriasis in adults and is being studied in the pediatric population (6 to 17 years). A maximum of 132 participants will be enrolled in the study across approximately 50 sites worldwide. Participants will receive subcutaneous injection of risankizumab every 12 weeks for 204 weeks and are followed up for safety for 20 weeks after last dose. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 3 - 12 Weeks
ABBVIE INC.
Study Director
JNJ-77242113 for Plaque Psoriasis
Janssen Clinic, Las Vegas + 1 more
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinicaltrial
Study Director
Page 1 of 1
Frequently Asked Questions
Explore related conditions